A Phase 1/2 Multi-Center Trial of Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
Phase 1: To determine the recommended phase 2 dose (RP2D) of vorinostat in children, adolescents and young adults following allogeneic HCT. Phase 2: To determine the incidence of grade 2‐4 acute GVHD by day +100 in subjects who receive vorinostat in addition to standard GVHD prophylaxis after allogeneic BMT.
This is a prospective phase 1/2 trial designed to assess the hypothesis that vorinostat, in addition to standard graft versus host disease (GVHD) prophylaxis, is feasible and safe in children, adolescent and young adult patients. All subjects will undergo allogeneic BMT according to local site institutional practice.
MoreChild to Adult
Patients 3 years to 39 years of age undergoing allogeneic BMT for malignant hematologic disease.
Please contact study team for additional information.
Treatment
Childrens Hospital Colorado
Vanessa Fabrizio, MD, MS
Protocol Number: 20-2018
More information available at ClinicalTrials.gov: NCT03842696
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers